For an industry that’s been trained to assume “IRB” and “slough” are synonyms, “fast” can sound like a dirty word—especially when it comes to clinical trial quality. Yet, as many of my U.S. sponsors are discovering, speed doesn’t have to mean shortcuts.
I have watched Australia’s clinical research ecosystem spend the last decade building a reputation for efficiency and scientific rigor. Today, biometrics and data quality from Australian trials are not just accepted but actively welcomed by the FDA.
In this article, I want to discuss how Australian clinical trial partners deliver FDA-ready data, and what that means for sponsors’ studies.
Foreign data acceptance in the U.S. is codified in FDA section 21. CFR 312.120, which allows data from non-U.S. studies to support an IND if the trial:
Australia’s Therapeutic Goods Administration (TGA) operates under those same principles through the Clinical Trial Notification (CTN) and Clinical Trial Approval (CTA) schemes.
Both systems are grounded in the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, which are an international standard for conducting clinical trials involving human subjects. Similarly, both systems are evolving toward the recently finalized ICH E6 (R3) framework, which emphasizes proportionate quality management and risk-based monitoring.
In short: Australia’s data standards speak FDA’s language fluently.
When structured correctly, Australian data are indistinguishable—in format, integrity, and regulatory acceptability—from U.S. data. The difference lies in the front-end efficiency: faster ethics review, streamlined governance, and pre-validated infrastructure.
Late last year, I was able to bring together colleagues from both the United States and Australia to discuss , Why Australia Is the Best Kept Secret in Early-Phase Clinical Trials. We explored why faster is not synonymous with shortcuts in the ANZ context, but rather a benefit of a differently designed system.
Myself and my co-panelists shared our insights on how Australia’s regulatory framework simplifies early-phase initiation: sponsors don’t need to compile an independent Chemistry, Manufacturing, and Controls (CMC) dossier or a standalone preclinical toxicology package. Instead, all necessary information is contained in the Investigator’s Brochure (IB).
The steps to approval are as simple as one, two!
One of my co-panelists addressed a common U.S. misconception succinctly:
“Many biotech sponsors assume they need an open Investigational New Drug (IND) application with the FDA to run a Phase I trial. In reality, Australia allows early-phase studies to proceed independently under CTN/CTA, provided the work complies with 21 CFR 312, which governs foreign studies intended to support an IND.”
That means the FDA can – and regularly does! – accept data from Australian trials so long as it’s conducted under GCP and the data are verifiable through inspection.
We also made sure to tie this operational clarity back to strategy. The key for U.S. sponsors seeking to work here is that Phase I strategy in Australia should complement the sponsor’s overall IND roadmap. Well-designed Australian trials can fill safety or dose-finding gaps that strengthen, rather than undermine, an eventual U.S. IND submission.
In my experience, this mirrors what more and more international sponsors are realizing: an Australian early-phase program is not an offshoot, but a launch pad in and of itself.
I encourage all of my sponsors to be strategic and evidence-based in the decisions they make.Three major industry shifts should push learning more about Australian regulatory standards to the top of your priority list:
Complete Phase has long operated under these principles, making its biometrics and clinical operations naturally aligned with what global regulators now expect.
Complete Phase’s validated eClinical environment, CDISC-ready programming, and ALCOA+ practices give sponsors confidence that their data will meet FDA inspection standards.
Complete Phase specializes in structuring Australian early-phase studies that not only stand alone scientifically, but directly support downstream IND strategy.
I’ve been very deliberate about equipping Complete Phase with the tools to support U.S. sponsors starting their trials on Australian ground. Together, these shifts create the strongest environment yet for U.S. sponsors to benefit from Australia’s rapid start-up timelines without compromising FDA readiness.
You don’t have to choose between speed and quality. In a landscape where every month saved can influence valuation, funding runway, or patient access, combining Australia’s efficiency with Complete Phase’s regulatory depth makes “fast but no shortcuts” a strategic advantage rather than a trade-off.
FDA 21 CFR 312.120: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-F/section-312.120
FDA Guidance on Acceptance of Foreign Clinical Studies: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-acceptance-foreign-clinical-studies-not-conducted-under-ind-frequently-asked-questions
ICH E6 (R3) GCP Guideline (Step 4, 2025): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
TGA Clinical Trial Handbook: https://www.tga.gov.au/resources/guidance/australian-clinical-trial-handbook
TGA CTN Scheme Overview: https://www.tga.gov.au/products/unapproved-therapeutic-goods/clinical-trials/clinical-trial-notification-ctn-scheme
FDA Study Data Standards Catalog: https://www.fda.gov/industry/fda-data-standards-advisory-board/study-data-standards-catalog
FDA Guidance on Electronic Systems and Signatures (2023): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions-and
FDA Guidance on Decentralized Clinical Trials (2024): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/decentralized-clinical-trials-drugs-biological-products-and-devices